Alliance for Clinical Trials in Oncology

02/13/2026

Alliance investigators shared promising research findings at :
🔹 Re**al Cancer: The Janus Re**al Cancer Trial explores treatment approaches that may help preserve organs while still achieving strong outcomes.
🔹 Colon Cancer: How physical activity may support better recovery for patients based on their tumor biology.
🔹 Metastatic Colorectal Cancer: How biomarkers can help personalize treatments.
Learn more https://bit.ly/Alliance-GI

02/12/2026

New prostate cancer trial! Thomas Hope, MD, of the University of California San Francisco, and
and Deaglan McHugh, MD, of Memorial Sloan Kettering Cancer Center, lead Alliance A032304, a phase III study to optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in prostate cancer. Read the news release and learn eligibility criteria https://bit.ly/AllianceA032304.

02/11/2026

🔍 New publication alert!
Data from Alliance A032201 has uncovered a genetic factor that may inform the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Published in Clinical and Translational Science by lead authors Michael Morris, MD, of Memorial Sloan Kettering Cancer Center and Nadine Norris, PhD, of the Mayo Clinic, this secondary analysis of could lead to more personalized treatments for patients.
🔗 Learn more: https://bit.ly/Alliance-A012301

02/10/2026

🚀 The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial (Alliance A032302) — a large study to answer a critical question:
👉 Can adding chemotherapy (docetaxel) to hormone therapy and apalutamide improve survival for men with metastatic prostate cancer?
Lead Investigator:
🔹 Deepak Kilari, MD – Froedtert & Medical College of Wisconsin
This trial is recruiting 1,200 participants and includes gene analysis to personalize treatment. Learn more: 🔗 http://bit.ly/AllianceA032302

02/09/2026

At the Alliance for Clinical Trials in Oncology, our mission goes beyond conducting studies—we strive to share the stories behind the science, connecting providers and patients with the latest treatment findings. Every trial represents hope, collaboration, and the relentless pursuit of better outcomes for patients. From groundbreaking clinical trials to innovative treatment strategies, our work is making headlines—and more importantly, making an impact.

These stories highlight how research transforms lives and shapes the future of cancer care. We invite you to explore some of our recent media coverage and learn how the Alliance is advancing cancer research through collaboration, innovation, and patient-centered care. Learn more at https://bit.ly/JanMedia

02/06/2026

Now enrolling! The Alliance for Clinical Trials in Oncology has a new study focused on rare adrenal cancers.
✅ It explores targeted therapies designed to attack specific molecular pathways driving these cancers.
✅ The study leverages precision medicine to match patients with treatments based on tumor biology.
✅ It aims to improve outcomes for patients facing limited options today.
🔗 Learn more about A092204 and eligibility: https://bit.ly/A092204-Konda

02/05/2026

Findings from the CALGB (Alliance) 80702 trial were recently published in JAMA Oncology. This study demonstrates how a ctDNA blood test can guide the use of NSAIDs (celecoxib) after surgery for stage III colon cancer:
✅ Patients with detectable ctDNA (indicating residual disease) experienced significantly improved survival when celecoxib was added after chemotherapy.
✅ Patients without ctDNA did not benefit, helping avoid unnecessary treatment.
🔗 Learn more: https://bit.ly/JAMA-NSAID

02/04/2026

The Alliance is committed to more than discovering new and better ways to treat cancer — we’re equally focused on preventing it.
On this , we’re taking a moment to highlight the essential role of prevention in reducing the risk of cancer before it starts. Prevention isn’t one action — it’s a combination of healthier choices, early detection, community education, and access to resources that empower people to protect their long term health.
From reducing to***co use and limiting exposure to harmful substances, to regular screenings and genetic testing for at-risk groups, prevention strategies have the power to save lives and reduce the burden of cancer across communities. The science is clear: when we invest in prevention, we change the future.
Learn more about our active cancer control trials that are making a real difference at https://bit.ly/Prevent26

02/04/2026

The Alliance is committed to more than discovering new and better ways to treat cancer — we’re equally focused on preventing it.
On this , we’re taking a moment to highlight the essential role of prevention in reducing the risk of cancer before it starts. Prevention isn’t one action — it’s a combination of healthier choices, early detection, community education, and access to resources that empower people to protect their long term health.
From reducing to***co use and limiting exposure to harmful substances, to regular screenings and genetic testing for at-risk groups, prevention strategies have the power to save lives and reduce the burden of cancer across communities. The science is clear: when we invest in prevention, we change the future.
Learn more about our active cancer control trials that are making a real difference at https://bit.ly/Prevent26

Alliance National Clinical Trials Network

02/03/2026

New Clinical Trial Alert: Alliance A232402 CD – The PAGODA Trial, focused on improving care for people with gastrointestinal cancers
This study, led by Gabriel Brooks, MD, MPH, of Dartmouth Geisel School of Medicine, aims to prevent treatment delays, which can significantly impact outcomes for patients. By addressing barriers and streamlining care, the PAGODA Trial seeks to ensure timely and effective treatment for those who need it most.
Learn at https://bit.ly/PAGODA26.

02/02/2026

The trial is now enrolling patients with colorectal cancer that has spread beyond the liver. This study is designed for individuals who:
✅ Responded well to initial chemotherapy
✅ Have up to 4 treatable cancer sites
This trial aims to explore innovative approaches to improve outcomes for patients facing complex metastatic disease.
Learn more and see if you or someone you know may be eligible: https://bit.ly/Alliance-A022101

02/02/2026

🚨 New Findings in Prostate Cancer Symptom Management
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin significantly reduces hot flashes in men undergoing hormone therapy for prostate cancer. The results from Alliance A222001, led by Bradley Stish, MD, of the Mayo Clinic, were just published in the Journal of Clinical Oncology.
Hot flashes affect up to 80% of men receiving androgen deprivation therapy, often disrupting sleep, energy levels, and quality of life. This study shows that oxybutynin—commonly used for overactive bladder—offers clinically meaningful improvements in both symptom frequency and severity.
Key findings include:
• Both 2.5 mg and 5 mg twice daily doses significantly outperformed placebo
• Improvements were seen as early as the first week
• Up to 79% of participants on the higher dose achieved at least a 50% reduction in hot flash scores
• Treatment was generally well tolerated, with dry mouth as the most common side effect
Learn more at https://bit.ly/Stish-JCO.